Site Map

Home
Efficacy—Adjuvant
- Study Design
- 10-Year Relapse-Free Survival
- 10-Year Distant Metastasis-Free Survival
- 10-Year Overall Survival
- BRAF V600E/K Prevalence
- Real-World Evidence
Efficacy—Metastatic
- Study Designs
- 5-Year OS and PFS—COMBI-v
- 5-Year Response Rates–Pooled COMBI-d/v Analysis
- Time to Response
- Efficacy in Patients With Brain Metastases
Safety Profile
- Adverse Reactions—Adjuvant
- Adverse Reactions—Metastatic
- Adverse Events Declined Over Time
- Strategies for Managing Pyrexia
About BRAF+ Melanoma
Dosing & Administration
- Recommended Dosing
- Dose Reductions
- Recommended Dose Modifications
Mechanism of Action
Access
- Novartis Patient Support™
- Novartis Oncology Universal Co-pay Program
Surgeon Center
- Information for Surgeons
- Resources
Resources
- HCP Resources
- Patient Website
Video & Podcast Library
- Adjuvant Videos
- Metastatic Videos
- AE Management Videos
- Medical Expert Podcasts
Home
Efficacy
- Study Design of Clinical Trial
- 1L Patients: Response Rates
- Patient Characteristics
Safety Profile
- Adverse Reactions (ARs)
- Treatment-Emergent Laboratory Abnormalities
- Discontinuation Rates
- Incidence of Pyrexia
- Recommended Dose Modifications for ARs
Dosing & Administration
- Recommended Dose
- Dose Modifications
- Storage and Handling
Testing for BRAF V600E Mutation in mNSCLC
- Why Test for BRAF V600E
- When to Test for BRAF V600E
- How to Test for BRAF V600E
Access
- Novartis Patient Support™
- Universal Co-pay Program (UCP)
Resources
- Patient Resources
- TAFINLAR + MEKINIST Patient Website
- For Your Practice
Mechanism of Action
Video Library
- Test at Diagnosis and Take Action in mNSCLC
- TAF+MEK in Patients With BRAF V600E-Mutant mNSCLC
Home
Efficacy
- Study Designs
- Response Rates (Adult and Pediatric Patients)
- Duration of Response Across Multiple Tumor Types
Safety Profile
- Adverse Reactions (Adult)
- Adverse Reactions (Pediatric)
Dosing & Administration
- Adult Dosing and Dose Reductions
- Pediatric Dosing and Dose Reductions
- Recommended Dose Modifications
- Storage and Handling
BRAF Testing
About BRAF Mutations
Mechanism of Action
Access/Patient Support
- NOVARTIS PATIENT SUPPORT™
- Novartis Oncology Universal Co-Pay Program
Resources
Home
Efficacy
- Study Design
- Response Rates
- Progression-Free Survival
Safety Profile
- Adverse Reactions (ARs)
- Adverse Reactions and Treatment Discontinuation
Dosing & Administration
- Capsule & Tablet Dosing
- Liquid Formulation Dosing
- Capsule & Tablet Dose Reductions
- Liquid Dose Reductions
- Dose Modifications
About BRAF V600E
- BRAF Mutations In Pediatric Glioma
- BRAF Mutation Testing
Resources
- BRAF V600E+ pLGG Caregiver Brochure
- BRAF V600E+ pLGG HCP Brochure
Video Library